Drug Interactions
Comprehensive guide to drug-drug interactions, pharmacokinetic interactions, and interaction management.
Browse the pages below for detailed information.
nemolizumab — Interleukin-31 receptor, α subunit Interaction
Drug-target interaction between nemolizumab and Interleukin-31 receptor, α subunit. Antibody pharmacological agent targeting this protein.
neratinib — erb-b2 receptor tyrosine kinase 2 Interaction
Drug-target interaction between neratinib and erb-b2 receptor tyrosine kinase 2. Synthetic organic pharmacological agent targeting this protein.
nilotinib — ABL proto-oncogene 1, non-receptor tyrosine kinase Interaction
Drug-target interaction between nilotinib and ABL proto-oncogene 1, non-receptor tyrosine kinase. Synthetic organic pharmacological agent targeting this protein.
nilutamide — Androgen receptor Interaction
Drug-target interaction between nilutamide and Androgen receptor. Synthetic organic pharmacological agent targeting this protein.
nimesulide — COX-1 Interaction
Drug-target interaction between nimesulide and COX-1. Synthetic organic pharmacological agent targeting this protein.
nimesulide — COX-2 Interaction
Drug-target interaction between nimesulide and COX-2. Synthetic organic pharmacological agent targeting this protein.
nimodipine — Mineralocorticoid receptor Interaction
Drug-target interaction between nimodipine and Mineralocorticoid receptor. Synthetic organic pharmacological agent targeting this protein.
nintedanib — fms related receptor tyrosine kinase 4 Interaction
Drug-target interaction between nintedanib and fms related receptor tyrosine kinase 4. Synthetic organic pharmacological agent targeting this protein.
nipocalimab — Fc fragment of IgG receptor and transporter Interaction
Drug-target interaction between nipocalimab and Fc fragment of IgG receptor and transporter. Antibody pharmacological agent targeting this protein.
niraparib — poly(ADP-ribose) polymerase 1 Interaction
Drug-target interaction between niraparib and poly(ADP-ribose) polymerase 1. Synthetic organic pharmacological agent targeting this protein.
niraparib — poly(ADP-ribose) polymerase 2 Interaction
Drug-target interaction between niraparib and poly(ADP-ribose) polymerase 2. Synthetic organic pharmacological agent targeting this protein.
nitisinone — 4-hydroxyphenylpyruvate dioxygenase Interaction
Drug-target interaction between nitisinone and 4-hydroxyphenylpyruvate dioxygenase. Synthetic organic pharmacological agent targeting this protein.
nitrendipine — Cav1.3 Interaction
Drug-target interaction between nitrendipine and Cav1.3. Synthetic organic pharmacological agent targeting this protein.
nivolumab — programmed cell death 1 (CD279) Interaction
Drug-target interaction between nivolumab and programmed cell death 1 (CD279). Antibody pharmacological agent targeting this protein.
NO — Guanylyl cyclase, α1β1 Interaction
Drug-target interaction between NO and Guanylyl cyclase, α1β1. Inorganic pharmacological agent targeting this protein.
nomifensine — DAT Interaction
Drug-target interaction between nomifensine and DAT. Synthetic organic pharmacological agent targeting this protein.
nomifensine — NET Interaction
Drug-target interaction between nomifensine and NET. Synthetic organic pharmacological agent targeting this protein.
norethisterone — Progesterone receptor Interaction
Drug-target interaction between norethisterone and Progesterone receptor. Synthetic organic pharmacological agent targeting this protein.
nortriptyline — NET Interaction
Drug-target interaction between nortriptyline and NET. Synthetic organic pharmacological agent targeting this protein.
nortriptyline — SERT Interaction
Drug-target interaction between nortriptyline and SERT. Synthetic organic pharmacological agent targeting this protein.
obeticholic acid — Farnesoid X receptor Interaction
Drug-target interaction between obeticholic acid and Farnesoid X receptor. Synthetic organic pharmacological agent targeting this protein.
obinutuzumab — CD20 (membrane-spanning 4-domains, subfamily A, member 1) Interaction
Drug-target interaction between obinutuzumab and CD20 (membrane-spanning 4-domains, subfamily A, member 1). Antibody pharmacological agent targeting this protein.
ocrelizumab — CD20 (membrane-spanning 4-domains, subfamily A, member 1) Interaction
Drug-target interaction between ocrelizumab and CD20 (membrane-spanning 4-domains, subfamily A, member 1). Antibody pharmacological agent targeting this protein.
ofatumumab — CD20 (membrane-spanning 4-domains, subfamily A, member 1) Interaction
Drug-target interaction between ofatumumab and CD20 (membrane-spanning 4-domains, subfamily A, member 1). Antibody pharmacological agent targeting this protein.
olanzapine — 5-HT2A receptor Interaction
Drug-target interaction between olanzapine and 5-HT2A receptor. Synthetic organic pharmacological agent targeting this protein.
olanzapine — 5-HT2C receptor Interaction
Drug-target interaction between olanzapine and 5-HT2C receptor. Synthetic organic pharmacological agent targeting this protein.
olanzapine — D2 receptor Interaction
Drug-target interaction between olanzapine and D2 receptor. Synthetic organic pharmacological agent targeting this protein.
olaparib — poly(ADP-ribose) polymerase 1 Interaction
Drug-target interaction between olaparib and poly(ADP-ribose) polymerase 1. Synthetic organic pharmacological agent targeting this protein.
olaparib — poly(ADP-ribose) polymerase 2 Interaction
Drug-target interaction between olaparib and poly(ADP-ribose) polymerase 2. Synthetic organic pharmacological agent targeting this protein.
olaratumab — platelet derived growth factor receptor alpha Interaction
Drug-target interaction between olaratumab and platelet derived growth factor receptor alpha. Antibody pharmacological agent targeting this protein.
olmesartan — AT1 receptor Interaction
Drug-target interaction between olmesartan and AT1 receptor. Synthetic organic pharmacological agent targeting this protein.
olodaterol — β2-adrenoceptor Interaction
Drug-target interaction between olodaterol and β2-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
omalizumab — immunoglobulin heavy constant epsilon Interaction
Drug-target interaction between omalizumab and immunoglobulin heavy constant epsilon. Antibody pharmacological agent targeting this protein.
omeprazole — ATP4A Interaction
Drug-target interaction between omeprazole and ATP4A. Synthetic organic pharmacological agent targeting this protein.
ondansetron — 5-HT3A Interaction
Drug-target interaction between ondansetron and 5-HT3A. Synthetic organic pharmacological agent targeting this protein.
ondansetron — 5-HT3AB Interaction
Drug-target interaction between ondansetron and 5-HT3AB. Synthetic organic pharmacological agent targeting this protein.
ongericimab — proprotein convertase subtilisin/kexin type 9 Interaction
Drug-target interaction between ongericimab and proprotein convertase subtilisin/kexin type 9. Antibody pharmacological agent targeting this protein.
opicapone — Catechol-O-methyltransferase Interaction
Drug-target interaction between opicapone and Catechol-O-methyltransferase. Synthetic organic pharmacological agent targeting this protein.
oprelvekin — Interleukin-11 receptor Interaction
Drug-target interaction between oprelvekin and Interleukin-11 receptor. Peptide pharmacological agent targeting this protein.
orciprenaline — β2-adrenoceptor Interaction
Drug-target interaction between orciprenaline and β2-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
orlistat — pancreatic lipase Interaction
Drug-target interaction between orlistat and pancreatic lipase. Synthetic organic pharmacological agent targeting this protein.
ospemifene — Estrogen receptor-α Interaction
Drug-target interaction between ospemifene and Estrogen receptor-α. Synthetic organic pharmacological agent targeting this protein.
ospemifene — Estrogen receptor-β Interaction
Drug-target interaction between ospemifene and Estrogen receptor-β. Synthetic organic pharmacological agent targeting this protein.
oxaprozin — COX-1 Interaction
Drug-target interaction between oxaprozin and COX-1. Synthetic organic pharmacological agent targeting this protein.
oxaprozin — COX-2 Interaction
Drug-target interaction between oxaprozin and COX-2. Synthetic organic pharmacological agent targeting this protein.
oxiglutatione — glutathione-disulfide reductase Interaction
Drug-target interaction between oxiglutatione and glutathione-disulfide reductase. Synthetic organic pharmacological agent targeting this protein.
oxybutynin — M1 receptor Interaction
Drug-target interaction between oxybutynin and M1 receptor. Synthetic organic pharmacological agent targeting this protein.
oxybutynin — M3 receptor Interaction
Drug-target interaction between oxybutynin and M3 receptor. Synthetic organic pharmacological agent targeting this protein.
oxymetazoline — α1A-adrenoceptor Interaction
Drug-target interaction between oxymetazoline and α1A-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
oxymetazoline — α2A-adrenoceptor Interaction
Drug-target interaction between oxymetazoline and α2A-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
oxytocin — OT receptor Interaction
Drug-target interaction between oxytocin and OT receptor. Peptide pharmacological agent targeting this protein.
ozanimod — S1P1 receptor Interaction
Drug-target interaction between ozanimod and S1P1 receptor. Synthetic organic pharmacological agent targeting this protein.
ozanimod — S1P5 receptor Interaction
Drug-target interaction between ozanimod and S1P5 receptor. Synthetic organic pharmacological agent targeting this protein.
P-Glycoprotein Interactions
P-glycoprotein (P-gp) is an efflux transporter that affects drug absorption, distribution, and elimination. P-gp interactions can alter the pharmacokinetics of substrate drugs.
paclitaxel — tubulin beta class I Interaction
Drug-target interaction between paclitaxel and tubulin beta class I. Natural product pharmacological agent targeting this protein.
pacritinib — Janus kinase 2 Interaction
Drug-target interaction between pacritinib and Janus kinase 2. Synthetic organic pharmacological agent targeting this protein.
palbociclib — cyclin dependent kinase 4 Interaction
Drug-target interaction between palbociclib and cyclin dependent kinase 4. Synthetic organic pharmacological agent targeting this protein.
palbociclib — cyclin dependent kinase 6 Interaction
Drug-target interaction between palbociclib and cyclin dependent kinase 6. Synthetic organic pharmacological agent targeting this protein.
palifermin — fibroblast growth factor receptor 2 Interaction
Drug-target interaction between palifermin and fibroblast growth factor receptor 2. Peptide pharmacological agent targeting this protein.
palonosetron — 5-HT3A Interaction
Drug-target interaction between palonosetron and 5-HT3A. Synthetic organic pharmacological agent targeting this protein.